Aller-7® TreatsAirborne Allergies

March 28, 2005

1 Min Read
SupplySide Supplement Journal logo in a gray background | SupplySide Supplement Journal


Aller-7® TreatsAirborne Allergies

BENICIA, Calif.A multicenterclinical trial spanning three years and involving 545 patients with allergicrhinitis confirmed the safety and efficacy of Aller-7®, a patented nutritionalingredient from InterHealth Nutraceuticals (Int J ClinPharmacol Res, 24, 2-3:79-94, 2004). The study wascoordinated by the ASA Foundation. Researchers found over a period of 12 weeks,94 percent of patients in open label trials and 92 percent of patients in doubleblind, placebo-controlled trials treated with Aller-7 reported an improvement insymptoms ranging from 40 percent to 100 percent. In addition to relief fromsneezing, running nose and nasal congestion, improvement was also observed inabsolute eosinophil count, mucociliary clearance time and peak nasal flow rate. No serious side effects were reported.

Aller-7 is taken as a dietary supplement before allergyseason starts or even all year round, if perennial breathing difficulties are aproblem, making it an ideal long-term solution without debilitating sideeffects, said Skip Seroy, president of InterHealth(www.interhealthusa.com). Aller-7 is a patented blend of seven Indian herbal extracts,including Piper longum, Zingiberofficinale and Terminaliachebula.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like